



BAUSCH + LOMB

1Q26

Financial Results

April 29, 2026

Forward-Looking Statements; Non-GAAP Information

This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L"), including the Company's 2026 full-year guidance, our 3-year strategic plan and the targets, components and steps thereof, our anticipated growth drivers and the expected timing and impact thereof, our focus on pipeline innovation, anticipated timing for the commencement and completion of studies and other development work respecting our pipeline products and the expected outcomes of such development work, anticipated submission, approval and launch dates of such products, the anticipated geographic expansions and planned line extensions for certain of our products, the expected market acceptance and performance for our products and pipeline products, and the expected market size and growth for certain of the markets in which we have or expect to have products. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "predicts," "projects," "goals," "intends," "plans," "should," "could," "would," "may," "might" "will," "strive," "believes," "estimates," "potential," "target," "commit," "forecast," "outlook," "guidance," "tracking," or "continue" and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's 2026 full-year guidance and 3-year strategic plan, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators (the "CSA") (including the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (which was filed with the SEC and CSA on February 18, 2026) and its most recent quarterly filings), which factors are incorporated herein by reference. They also include risks and uncertainties respecting the proposed plan to separate the Company into an independent, publicly traded company, separate from the remainder of Bausch Health Companies Inc. ("BHC") (the "separation"), which include, but are not limited to, the expected benefits and costs of the separation, the expected timing of completion of the separation and its manner and terms (including that it may include the transfer of all or a portion of BHC's remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the "distribution")), the expectation that, if the separation is to be effected through a distribution, then it will be completed following the achievement of targeted debt leverage ratios, subject to market conditions and receipt of applicable shareholder and other necessary approvals and other factors (including those described in BHC's public statements), the ability to complete the distribution considering the various conditions to the completion of the distribution (some of which are outside the Company's and BHC's control, including conditions related to regulatory matters and receipt of applicable shareholder and other approvals), the impact of any potential sales or dispositions of the Company's common shares by BHC (including in connection with a foreclosure on the Bausch + Lomb common shares owned by BHC or its subsidiaries that are or may be pledged as collateral for certain of BHC's or its subsidiary's debt), that market or other conditions are no longer favorable to completing the transaction, that applicable shareholder, stock exchange, regulatory or other approval is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation, diversion of management time on separation-related issues, retention of existing management team members, the reaction of customers and other parties to the separation, the structure of the distribution, the qualification of the distribution as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and BHC to satisfy the conditions required to maintain the tax-free status of the distribution (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the distribution, the potential dis-ynergy costs resulting from the separation, the impact of the separation on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments and legal and regulatory rules affecting the Company's business. In particular, the Company can offer no assurance that the separation will occur at all, or that any such transaction will occur on the terms and timelines or in the manner anticipated by the Company and BHC. They also include risks and uncertainties relating to acquisitions and other business development transactions the Company has completed or may, in the future, pursue and complete, including risks that pending transactions may not close, risks that the Company may not realize the expected benefits of those transactions on a timely basis or at all and, where applicable, risks relating to increased levels of debt as a result of debt incurred to finance such transactions, including in regards to compliance with our debt covenants. They also include risks and uncertainties related to the impacts of the new legislation commonly referred to as One Big Beautiful Bill Act, including the effects on our tax provision for both 2026 and future years. They also include the expected impact of the tariffs imposed by the U.S. and counter-tariffs or other retaliatory measures imposed on the U.S. by other countries and disruptions to global supply chains and other potential results as a result of these developments and our ability to successfully manage the expected impact of such tariffs and counter-tariffs and other measures, including the success of our planned actions and levers to manage these matters as well as the impact of potential tariff refunds or recoveries, if any. They also include risks and uncertainties related to our ability to adopt and integrate artificial intelligence solutions into various aspects of our business and operations responsibly and in compliance with applicable legislation, laws, rules, regulation and guidance. Finally, they also include, but are not limited to, risks and uncertainties caused by or relating to a potential recession and other adverse economic conditions (such as heightened inflation and interest rates, fluctuations in exchange rates, and slower growth and risk and uncertainties associated with the conflict in the Middle East),

which could adversely impact our revenues, expenses and resulting margins. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. In addition, Management has also made certain assumptions regarding our 2026 full-year guidance with respect to expectations regarding base performance growth, business performance, currency impact, impacts of inflation, the company's ability to offset the impact of tariffs in 2026 (based on the current tariff policy and the actions the company is taking to manage these measures), adjusted gross margin (non-GAAP), adjusted SG&A expense (non-GAAP) and the Company's ability to continue to manage such expense in the manner anticipated, net interest expense (which will vary based on, among other things, interest rates and our indebtedness), adjusted tax rate, and full year capex and the anticipated timing and extent of the Company's R&D expense.

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.

The guidance in this presentation is only effective as of the date given, April 29, 2026. Distribution or reference of this deck following April 29, 2026 does not constitute the Company updating guidance.

Non-GAAP Information: To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures and ratios, including (i) Constant Currency Change/Constant Currency Growth/Constant Currency Revenue Growth (also referred to as "cc"), (ii) EBITDA, (iii) Adjusted EBITDA, (iv) Adjusted EBITDA Margin, (v) Adjusted EBITDA excluding Acquired IPR&D, (vi) Adjusted EBITDA Margin excluding Acquired IPR&D, (vii) Adjusted EBITDA growth (excluding Acquired IPR&D), (viii) Adjusted EBITA, (ix) Adjusted Gross Profit, (x) Adjusted Gross Margin, (xi) Adjusted R&D, (xii) Adjusted SG&A and Adjusted SG&A margin, (xiii) Adjusted Net Income (Loss) attributable to Bausch + Lomb, (xiv) Adjusted Earnings Per Share ("EPS") attributable to Bausch + Lomb, (xv) Adjusted EPS Attributable to Bausch + Lomb excluding Acquired IPR&D, (xvi) Adjusted Cash Flow from Operations/Adjusted Cash used by Operations, (xvii) Adjusted Tax Rate and (xviii) Net Leverage. Management uses some of these non-GAAP measures and ratios as key metrics in the evaluation of Company performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance and the valuation of the Company. In addition, these non-GAAP measures and ratios, address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures and ratios are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP measures and ratios of other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the appendix hereto. However, for outlook purposes, the Company does not provide reconciliations of projected Adjusted Gross Margin (non-GAAP) to projected GAAP Gross Margin, projected Constant Currency Revenue Growth to projected GAAP Revenue Growth, projected Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) to projected GAAP net income (loss), projected Adjusted EBITDA growth (excluding Acquired IPR&D) to projected GAAP net income growth or projected Adj. EBITDA margin (excl. Acq. IPR&D) to projected GAAP net income (loss) margin or the components of projected net leverage to GAAP equivalents (project net debt to debt and projected Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) to projected GAAP net income (loss)), in each case, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, could result in the GAAP measure or ratio being materially different from the projected non-GAAP measure or ratio.

For further information on non-GAAP financial measures and ratios, please see the Appendix.

Q1 Highlights

Financial Results & Outlook

Growth Drivers



Delivering Growth + P&L Leverage

+6%

Constant Currency
Revenue Growth^{1,2}

+59%

Adj. EBITDA Growth
(Ex. Acq. IPR&D)^{1,2,3,4}

16.1%

Adj. EBITDA Margin
(Ex. Acq. IPR&D)^{2,4}

Turning Strategy Into Results¹

1

Sustaining Growth & Driving Margin Expansion

+6% CC^{2,3} revenue growth vs 1Q25,
+12% CC^{2,3} growth in Pharma

\$200M Adj. EBITDA (ex. Acq. IPR&D)³
+59% growth vs. 1Q25

2

Enhancing Selling & Operational Excellence

Strong revenue growth across key brands⁴:
+33% Miebo®, +30% Xiidra®, +25% DD SiHy

Productivity gains driven by
enhanced AI capabilities

3


Advancing Pipeline Innovation

Lumify NXT^{TM5} NDA filed,
seeLYRATM CE submission completed

All trial recruitment progressing –
BL1107 (Glaucoma), enVista BeyondTM,
Dual-Action DED⁶, BL1332 (OSP⁷)


Executing On Our 3-Year Plan

Margin Expansion in 2025



FY25 Quarterly Adj. EBITDA Margin
(ex. Acq. IPR&D)¹


Momentum into 2026



CC Revenue Growth^{1,2}


Adj. EBITDA Margin
(ex. Acq. IPR&D)¹

Advancing 2026 R&D Milestones¹




Driving Broad-Based Growth Across Brands¹

B+L CC Revenue Growth^{1,2}



B+L Reported Revenue



1Q26 Segment CC Revenue Growth^{1,2}

+5% Vision Care

+5% Contact Lens; +5% Consumer

+1% Surgical

+12% Pharmaceuticals

1Q26 Franchise Reported Growth³

Artelac® **+34%**

Miebo® **+33%**

enVista
ASPIRE
LUX enVista
ENVY **+32%**

xiidra® **+30%**

INFUSE®
ULTRA^{one} **+25%**

LUMIFY™ **+15%**

blink® **+6%**

ULTRA^{contact lenses}
monthly **+6%**

VISION27

At B+L Waterford we build on our
EXCELLENCE in contact lens manufacturing
while also driving change.

We are committed to fostering a culture of fearless innovation and
to ensure our relentless growth is
INNOVATION SUSTAINABLE FUTURE
for our employees, customers,
community and shareholders.




BAUSCH+LOMB
See better. Live better.

Financial Results

1Q26 Revenue Drivers

BAUSCH + LOMB




+9% 1Q26 Revenue Growth Reported

+6% 1Q26 Revenue Growth Constant Currency¹

Broad-based growth across brands


~\$42M revenue FX tailwinds

Vision Care




■ Consumer ■ Contact Lens

Surgical



■ Implantables ■ Equipment
■ Consumables/Other

Pharmaceuticals



■ U.S. ■ International

1 Q 2 6 C O N S T A N T C U R R E N C Y R E V E N U E G R O W T H ¹

+5%

Lens portfolio (+8%, +5% cc^{1,2}), U.S. (+6%) and Int'l (+9%, +4% cc^{1,2})

Consumer (+9%, +5% cc^{1,2}), Growth in Lumify®, Dry Eye, Vitamins

+1%

Implantables (+9%, +3% cc^{1,2}), Premium IOLs (+32%, +27% cc^{1,2})

Consumables (+8%, +2% cc^{1,2}), Equipment (+0%, -4% cc^{1,2})

+12%

Growth in U.S. Pharma (+14%) and Int'l Pharma (+14%, +7% cc^{1,2})

Led by strong growth in Miebo® (+33%) and Xiidra® (+30%)

1Q26 Bausch + Lomb P&L (Non-GAAP)¹

Bausch + Lomb	1Q26	1Q25	Reported Change	Constant Currency Change ¹
Vision Care Revenue	\$711M	\$656M	8%	5%
Surgical Revenue	\$228M	\$214M	7%	1%
Pharmaceuticals Revenue	\$305M	\$267M	14%	12%
Total Revenue	\$1,244M	\$1,137M	9%	6%
Adj. Gross Profit ¹	\$761M	\$677M	12%	9%
Adj. Gross Margin ¹	61.2%	59.5%	170 bps	
Adj. R&D ¹	\$101M	\$86M	(17%)	(15%)
Adj. SG&A ¹	\$534M	\$526M	(2%)	1%
Adj. EBITA ¹	\$115M	\$37M	211%	192%
Depreciation	\$44M	\$39M	13%	8%
Stock Based Compensation	\$34M	\$28M	21%	21%
Adj. EBITDA ^{1,2}	\$189M	\$98M	93%	83%
Adj. EBITDA (ex. Acq. IPR&D)^{1,2,3,4}	\$200M	\$126M	59%	51%
<i>Adj. EBITDA Margin (ex. Acq. IPR&D)^{1,3}</i>	16.1%	11.1%		
Adj. Net Income (Loss) Attributable to B+L ¹	\$19M	(\$54M)	135%	126%
Adj. EPS Attributable to B+L ¹	\$0.05	(\$0.15)		
Adj. EPS Attributable to B+L (ex. Acq. IPR&D)^{1,3}	\$0.08	(\$0.07)		

1Q26 Highlights

+6%

Constant Currency Revenue Growth¹

+59%

Adj. EBITDA Growth (Ex. Acq. IPR&D)^{1,2,3}

16.1%

Adj. EBITDA Margin (Ex. Acq. IPR&D)^{1,3}

1Q26 Bausch + Lomb P&L (GAAP)

Bausch + Lomb	1Q26	1Q25	Reported Change	Constant Currency Change ¹
Vision Care Revenue	\$711M	\$656M	8%	5%
Surgical Revenue	\$228M	\$214M	7%	1%
Pharmaceuticals Revenue	\$305M	\$267M	14%	12%
Total Revenue	\$1,244M	\$1,137M	9%	6%
Gross Profit	\$704M	\$588M	20%	16%
Gross Margin	56.6%	51.7%		
R&D	\$101M	\$86M	(17%)	(15%)
SG&A	\$544M	\$563M	3%	6%
Operating Income (Loss)	\$33M	(\$83M)		
Net Loss Attributable to B+L	(\$71M)	(\$212M)		
<i>Net Loss Margin</i>	<i>(5.7%)</i>	<i>(18.6%)</i>		
EPS Attributable to B+L	(\$0.20)	(\$0.60)		

Outlook



Raising FY26 Guidance¹

	Prior Guidance (Feb. 2026)	Current Guidance (April 2026)
Total Revenue	\$5.375B – \$5.475B	\$5.420B – \$5.520B
Adj. EBITDA (ex. Acq. IPR&D) ²	\$1.000B – \$1.050B	\$1.010B – \$1.060B
Key Assumptions		
Net Interest Expense ³	~\$365M	~\$365M
R&D (% of Total Revenue)	~7.5% – 8.0%	~7.5% – 8.0%
Adj. Tax Rate ²	~19%	~19%
Avg. Fully Diluted Share Count	~364M	~364M
CapEx	~\$285M	~\$285M
Depreciation and Stock Based Comp ⁴	~\$315M	~\$315M

**\$5.420 –
5.520B**

Revenue
Raising by \$45M⁵

+5.3 – 7.2%

CC Revenue Growth²
Raising by ~30 bps⁵ at Midpoint

**\$1.010 –
1.060B**

Adj. EBITDA (Ex. Acq. IPR&D)²
Raising by \$10M⁵

+16%

Adj. EBITDA Growth
(Ex. Acq. IPR&D)^{2,5}

~62%

Adj. Gross Margin²

+\$50M


FY26 Estimated Revenue
FX Tailwinds⁵

- The guidance in this presentation is only effective as of the date given, April 29, 2026, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this deck following April 29, 2026 does not constitute the Company re-affirming guidance. See Slide 1 for further information on forward-looking statements. This guidance does not take into consideration any changes in tariff policy, given the dynamic nature of the situation.
- This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures or ratios. See slides 10 to 11 for disclosure of historic non-GAAP measures and ratios and their historic comparable GAAP measures and ratios.
- Interest Expense includes interest on the outstanding \$2.8B of Term Loan, \$1.4B of October 2028 Senior Secured Notes, €675M January 2031 Senior Secured Notes, \$12M of term debt and \$150M drawn revolving credit facility (as of 4/29/2026), amortization and excludes write-down of financing fees.
- Does not include the potential expense acceleration of certain grants upon final separation.
- The increase in the anticipated full-year revenue is a result of strong business performance for the remainder of 2026 and an increase of \$20 million in expected currency tailwinds (a result of the weakening of the U.S. dollar relative to other currencies). The increases in anticipated constant currency revenue growth, anticipated full-year adjusted EBITDA (excluding acquired IPR&D) and anticipated adjusted EBITDA growth (excluding acquired IPR&D) is a result of strong business performance in the first quarter of 2026 and anticipated stronger business performance for the remainder of 2026.


Growth Drivers




Strengthening Consumer Leadership¹



Artelac[®]
+34%
1Q26 Reported Revenue Growth



blink[®]
+6%
1Q26 Reported Revenue Growth²



Eye Vitamins
PreserVision[®] OcuVite.
+2%
1Q26 Reported Revenue Growth




LUMIFY[®]
REDNESS RELIEVER EYE DROPS
+15%
1Q26 Reported Revenue Growth

...and Expanding Addressable Market^{1,2}

Addressing Nutritional Needs in All Stages of AMD to Expand Market by ~3x^{3,4}



Launching Now



Taking AREDS2 Supplements

AMD Diagnosed

Beauty Enthusiasts Represent Continued Growth Engine⁵




Beauty Positioning Supports Premium Pricing

Lumify NXT Launch: 1H27^{1,6}
(formerly Lumify Luxe)


Delivering Miebo & Xiidra Revenue Growth¹



Miebo[™]
(perfluorohexyloctane
ophthalmic solution)



xiidra[®]
(lifitegrast
ophthalmic solution)5%



Driving Lens Growth, Long Runway Ahead^{1,2}

+5%

1Q26 Contact Lens
CC Revenue Growth³

+23%

1Q26 SiHy Franchise
CC Revenue Growth³

2026

2027

2028

2029

➤ Global Roll-
Out of DD
SiHy MF &
Toric


➤ Launch
DD SiHy
MF Toric⁴

➤ Launch
First-Of-Its-
Kind
Bioactive
Material⁴

➤ Launch
2nd DD SiHy⁴

➤ Launch
Premium
FRP SiHy⁴

➤ Launch
Myopia
Control⁴



Expanding Premium IOL Portfolio¹

+27%

CC Revenue Growth
in Premium IOLs²



enVista™
HYDROPHOBIC ACRYLIC IOL
ENVY

Launching in Europe

enVista Envy is the first diffractive premium IOL from Bausch + Lomb in Europe

Expanding Platform

Two full range of vision premium IOLs now available in Europe - enVista Envy and LuxLife

Executing Portfolio Strategy

Continued mix shift toward higher-margin categories to drive revenue growth and margin expansion

Built to Deliver Growth Into Next Decade¹



Q&A

R&D



TEACH-IN

SERIES

SAVE THE DATE: June 1, 2026



Miss our inaugural R&D
Teach-in on glaucoma?
Scan for replay

Appendix

Early Stage Launches and Pipeline Products to Watch¹

PRODUCT	DESCRIPTION	CATALYSTS TO WATCH
PHARMA		
Dual-Action Lifitegrast	First dual-action therapeutic to address evaporative and inflammatory dry eye	Phase 2b clinical study topline results expected 2H26
Ocular Pain	First-in-class therapy for ocular surface pain (OSP)	Phase 2 clinical study topline results expected 2H26
Glaucoma Neuroprotection siRNA	First glaucoma therapy to improve visual function and lower intraocular pressure	Phase 2b clinical study topline results expected 2H26
	Small interfering RNA treatment for geographic atrophy (GA)	Elevation of first program in GA into development in 2H26
SURGICAL		
IOL Portfolio		
• enVista Envoy®	Trifocal IOL – launched in Canada, U.S. and Europe	Expected rollout in Singapore and Hong Kong
• enVista Beyond™	Extended depth of focus (EDOF) IOL – clinical study ongoing	Registration clinical study topline results expected 2H26
• LuxLife®	Continuous full range of vision IOL – approved in EU	EU launch in process
ELIOS®	Implant free minimally invasive glaucoma surgery (MIGS) using excimer laser	Launched in EU; U.S. launch expected 2H26
seeNOVA™	Surgical platform for anterior, posterior and combined procedures	Development in process
seeLYRA™	Next-generation femtosecond laser	CE mark submitted and 510k submission expected in 1H26
VISION CARE		
Contact Lens		
• Bioactive Lens	Novel material design for daily disposable contact lens	Second external study expected to start in 2H26
• Myopia Control	Myopia control contact lens – multi-year study ongoing	U.S. registration clinical study start (FPFV ²) expected 1H26
• 2 nd DD SiHy Lens	Affordable innovation in a cost-competitive daily disposable	Expect to start external clinical study in 2H26
• FRP SiHy	SiHy lens designed to be premium FRP in the market	Expect to start external clinical study in 2H26
Consumer		
• Lumify NXT™	Enhanced formula for a more viscous new feel	NDA submitted, approval and launch expected 1H27
• AREDS3™ Vitamins	Next-generation eye vitamin formulation	Early launch in process
• Blink Triple Care® PF	Advanced preservative-free lipid based formulation	Early launch in process

Cash Flow and Balance Sheet Summary (1Q26)

	1Q26
Cash Flow From Operations	\$32M
Adj. Cash Flow From Operations (Non-GAAP) ^{1,2}	\$45M
Depreciation	\$44M
Stock Based Comp	\$34M
Net Interest ³	\$93M
CapEx	\$100M

Top 10 Revenue (Includes FX Impact)

Rank	Product / Franchise	1Q26	FY25	4Q25	3Q25	2Q25	1Q25
1	Surgical Consumables	\$117M	\$461M	\$123M	\$110M	\$120M	\$108M
2	Ocuvite® + PreserVision®	\$91M	\$429M	\$131M	\$106M	\$103M	\$89M
3	Xiidra®	\$87M	\$331M	\$95M	\$87M	\$82M	\$67M
4	Miebo®	\$76M	\$316M	\$112M	\$84M	\$63M	\$57M
5	Surgical Implantables	\$63M	\$214M	\$62M	\$50M	\$44M	\$58M
6	Bausch + Lomb Ultra®	\$57M	\$220M	\$57M	\$54M	\$55M	\$54M
7	SofLens®	\$55M	\$236M	\$64M	\$60M	\$58M	\$54M
8	Lumify®	\$55M	\$221M	\$63M	\$49M	\$61M	\$48M
9	Daily SiHy	\$55M	\$206M	\$57M	\$55M	\$50M	\$44M
10	Artelac®	\$51M	\$186M	\$50M	\$45M	\$53M	\$38M

Segment Reported Revenue

Vision Care	1Q26	1Q25	Reported Change	Constant Currency Change ¹
Contact Lens Revenue	\$254M	\$236M	8%	5%
Consumer Revenue	\$457M	\$420M	9%	5%
Total Revenue	\$711M	\$656M	8%	5%

Surgical	1Q26	1Q25	Reported Change	Constant Currency Change ¹
Implantables Revenue	\$63M	\$58M	9%	3%
Equipment Revenue	\$48M	\$48M	0%	(4%)
Consumables Revenue	\$117M	\$108M	8%	2%
Total Revenue	\$228M	\$214M	7%	1%

Pharmaceuticals	1Q26	1Q25	Reported Change	Constant Currency Change ¹
Total Revenue	\$305M	\$267M	14%	12%

Reported Revenue Trailing Quarters by Segment

Bausch + Lomb	1Q26	4Q25	3Q25	2Q25	1Q25
Vision Care					
Contact Lens	\$254M	\$271M	\$272M	\$258M	\$236M
Consumer	\$457M	\$507M	\$464M	\$495M	\$420M
Total Revenue	\$711M	\$778M	\$736M	\$753M	\$656M
Surgical					
Implantables	\$63M	\$62M	\$50M	\$44M	\$58M
Equipment	\$48M	\$64M	\$55M	\$52M	\$48M
Consumables	\$117M	\$123M	\$110M	\$120M	\$108M
Total Revenue	\$228M	\$249M	\$215M	\$216M	\$214M
Pharmaceuticals					
Total Revenue	\$305M	\$378M	\$330M	\$309M	\$267M

Non-GAAP Adjustments EPS Impact (\$M)²

	Three Months Ended March 31			
	2026		2025	
	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per Share Impact
Net loss attributable to Bausch + Lomb Corporation	\$ (71)	\$ (0.20)	\$ (212)	\$ (0.60)
Non-GAAP adjustments:				
Amortization of intangible assets	57	0.16	67	0.19
Restructuring, integration and transformation costs	17	0.05	38	0.11
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	3	0.01	14	0.04
Loss on Extinguishment of Debt and write-down of financing fees	7	0.02	-	-
Separation costs and separation-related costs	1	-	-	-
Gain on sale of assets	(3)	(0.01)	-	-
Other	7	0.02	2	0.01
Tax effect of non-GAAP adjustments	1	-	37	0.10
Total non-GAAP adjustments	90	0.25	158	0.45
Adjusted net income (loss) attributable to Bausch + Lomb Corporation (non-GAAP)¹	\$ 19	\$ 0.05	\$ (54)	\$ (0.15)
Acquired IPR&D	9	0.03	28	0.08
Adjusted net income (loss) attributable to Bausch + Lomb Corporation (non-GAAP)¹ Excluding Acquired IPR&D	\$ 28	\$ 0.08	\$ (26)	\$ (0.07)

Reconciliation of Reported Operating Income (Loss) to Adjusted EBITA (non-GAAP)¹ (\$M)

2026 GAAP

Amortization of intangible assets
 Gain on sale of assets
 Restructuring, integration and transformation costs
 Acquisition-related costs and adjustments (excluding amortization of intangible assets)
 Separation costs and separation-related costs
 Other

2026 Non-GAAP¹

1Q 2026					
Gross Profit	Gross Margin	SG&A	R&D Expense	Operating Income	
\$ 704	56.6%	\$ 544	\$ 101	\$ 33	
	57	4.6%			57
		0.0%			(3)
		0.0%	(9)		17
		0.0%			3
		0.0%	(1)		1
		0.0%			7
\$ 761	61.2%	\$ 534	\$ 101	\$ 115	

2025 GAAP

Amortization of intangible assets
 Restructuring, integration and transformation costs
 Acquisition-related costs and adjustments (excluding amortization of intangible assets)
 Separation costs and separation-related costs
 Other

2025 Non-GAAP¹

1Q 2025					
Gross Profit	Gross Margin	SG&A	R&D Expense	Operating (Loss) Income	
\$ 588	51.7%	\$ 563	\$ 86	\$ (83)	
	67	5.9%			67
		0.0%	(36)		38
	22	1.9%			14
		0.0%	(1)		
		0.0%			1
\$ 677	59.5%	\$ 526	\$ 86	\$ 37	

Reconciliation of Reported Net Loss to EBITDA (non-GAAP)¹ and Adjusted EBITDA (non-GAAP)¹ (\$M)

	Three Months Ended	
	March 31	
	2026	2025
Net loss attributable to Bausch + Lomb Corporation	\$ (71)	\$ (212)
Interest expense, net	93	91
Provision for income taxes	6	31
Depreciation and amortization of intangible assets	101	106
EBITDA¹	129	16
Adjustments:		
Restructuring, integration and transformation costs	17	38
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	3	14
Share-based compensation	34	28
Separation costs and separation-related costs	1	-
Loss on Extinguishment of Debt	1	-
Other non-GAAP Adjustments:		
Gain on sale of assets	(3)	-
Other	7	2
Adjusted EBITDA (non-GAAP)¹	\$ 189	\$ 98
Acquired IPR&D	11	28
Adjusted EBITDA (non-GAAP)¹ excluding Acquired IPR&D	\$ 200	\$ 126

Reconciliation of Reported Net Loss to EBITDA (non-GAAP)¹ and Adjusted EBITDA (non-GAAP)¹ (\$M)

	Three Months Ended			
	March 31 2025	June 30 2025	September 30 2025	December 31 2025
Net loss attributable to Bausch + Lomb Corporation	\$ (212)	\$ (62)	\$ (28)	\$ (58)
Interest expense, net	91	125	98	95
Provision for (benefit from) income taxes	31	(89)	22	71
Depreciation and amortization of intangible assets	106	107	109	99
EBITDA¹	16	81	201	207
Adjustments:				
Restructuring, integration and transformation costs	38	53	23	24
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	14	5	(2)	25
Share-based compensation	28	30	27	64
Loss on Extinguishment of Debt	-	9	(3)	-
Other non-GAAP Adjustments:				
Gain on sale of assets	-	-	(6)	-
Other	2	13	3	5
Adjusted EBITDA (non-GAAP)¹	\$ 98	\$ 191	\$ 243	\$ 326
Acquired IPR&D	28	1	-	4
Adjusted EBITDA (non-GAAP)¹ excluding Acquired IPR&D	\$ 126	\$ 192	\$ 243	\$ 330

Reconciliation of Reported Revenue to Constant Currency Revenue¹ and Constant Currency Revenue Growth¹ (\$M)

	Calculation of Constant Currency Revenue for the Three Months Ended			Change in		Change in		
	March 31, 2026		March 31, 2025	Reported Revenue		Constant Currency Revenue ¹		
	Revenue as Reported	Changes in Exchange Rates ²	Constant Currency Revenue (Non-GAAP) ¹	Revenue as Reported	Amount	Pct.	Amount	Pct.
Bausch + Lomb								
Vision Care	\$ 711	\$ (25)	\$ 686	\$ 656	\$ 55	8%	\$ 30	5%
Surgical	228	(12)	216	214	14	7%	2	1%
Pharmaceuticals	305	(5)	300	267	38	14%	33	12%
Total Bausch + Lomb	\$ 1,244	\$ (42)	\$ 1,202	\$ 1,137	\$ 107	9%	\$ 65	6%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and this Appendix for further information on non-GAAP measures and ratios.

2. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Reconciliation of Reported Revenue to Constant Currency Revenue¹ and Constant Currency Revenue Growth¹ (\$M)

	Calculation of Constant Currency Revenue for the Three Months Ended				Change in		Change in		
	March 31, 2026		Constant Currency Revenue (Non- GAAP) ¹	March 31, 2025		Reported Revenue		Constant Currency Revenue ¹	
	Revenue as Reported	Changes in Exchange Rates ²		Revenue as Reported	Amount	Pct.	Amount	Pct.	
Contact Lens	254	(7)	247	236	18	8%	11	5%	
Consumer	457	(17)	440	420	37	9%	20	5%	
Surgical Consumables	117	(7)	110	108	9	8%	2	2%	
Surgical Implantables	63	(3)	60	58	5	9%	2	3%	
Surgical Equipment	48	(2)	46	48	-	0%	(2)	-4%	
International Lens	152	(7)	145	140	12	9%	5	4%	
International Pharma	82	(5)	77	72	10	14%	5	7%	
Premium IOLs	29	(1)	28	22	7	32%	6	27%	
Daily SiHy	55	(1)	54	44	11	25%	10	23%	

Reconciliation of Reported Revenue to Constant Currency Revenue¹ and Constant Currency Revenue Growth¹ (\$M)

	Calculation of Constant Currency Revenue for the Twelve Months Ended				Change in		Change in	
	March 31, 2025		March 31, 2024		Reported Revenue		Constant Currency Revenue ¹	
	Revenue as Reported	Changes in Exchange Rates ²	Constant Currency Revenue (Non-GAAP) ¹	Revenue as Reported	Amount	Pct.	Amount	Pct.
Bausch + Lomb	\$ 1,137	\$ 19	\$ 1,156	\$ 1,099	\$ 38	3%	\$ 57	5%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and this Appendix for further information on non-GAAP measures and ratios.

2. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Non-GAAP Appendix

Description of Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures and ratios. These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to similar non-GAAP measures and ratios of other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

EBITDA/Adjusted EBITDA/Adjusted EBITDA Margin/Adjusted EBITDA excluding Acquired IPR&D/Adjusted EBITDA Margin excluding Acquired IPR&D/Adjusted EBITDA growth (excluding Acquired IPR&D)

EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is EBITDA (non-GAAP) further adjusted for the items described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that Adjusted EBITDA (non-GAAP) focuses management on the Company's underlying operational results and business performance. As a result, the Company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA margin (non-GAAP) is Adjusted EBITDA (non-GAAP) divided by Revenues.

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITDA (non-GAAP) is net income (loss) attributable to the Company (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization and the following items:

Asset impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions

and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes impairments of intangible assets from measuring the performance of the Company and its business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.

Restructuring, integration and transformation costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the B+L IPO, as the Company prepares for post-Separation operations, the Company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the Company's restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third party advisory costs, as well as certain compensation-related costs. Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the Company excludes the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration.

Share-based compensation: The Company excludes costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.

Non-GAAP Appendix

Adjusted EBITDA (non-GAAP) Adjustments (continued)

Separation costs and separation-related costs: The Company has excluded certain costs incurred in connection with activities taken to: (i) separate the Bausch + Lomb business from the remainder of BHC and (ii) register the Bausch + Lomb business as an independent publicly traded entity. Separation costs are incremental costs directly related to effectuating the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, legal, audit and advisory fees, talent acquisition costs and costs associated with establishing a new board of directors and audit committee. Separation-related costs are incremental costs indirectly related to the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, IT infrastructure and software licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Loss on extinguishment of debt: The company has excluded loss on extinguishment of debt as this represents a loss from refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market that are not in management's control. Bausch + Lomb did not have any material losses on extinguishment of debt prior to the second quarter of 2025.

Other Non-GAAP adjustments: The Company also excludes certain other amounts, including IT infrastructure investment, litigation and other matters, gain/(loss) on sales of assets and certain other amounts that are the result of other, non-comparable events to measure operating performance if and when present in the periods presented. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the Company believes these items are not routine operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not routine operating expenses. The Company excluded these costs as this event is outside of the ordinary course of continuing operations and is infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Adjusted EBITDA excluding Acquired In-Process Research and Development (IPR&D) is Adjusted EBITDA (non-GAAP) further adjusted to exclude Acquired IPR&D. Adjusted EBITDA Margin excluding Acquired In-Process Research and Development (IPR&D) is Adjusted EBITDA (non-GAAP) further adjusted to exclude Acquired IPR&D divided by Revenues. The IPR&D expenditures represent costs directly resulting from business development transactions and not through the normal course of business. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors in assessing our performance. However, investors should understand that the Company may enter into additional business development transactions in the future and, as a result, such acquired IPR&D may recur in the future. Adjusted EBITDA growth (excluding Acquired IPR&D) is changes in Adjusted EBITDA (excluding Acquired IPR&D) from period to period.

Adjusted Net Income (non-GAAP)

Adjusted net income (non-GAAP) is net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable GAAP financial measure) adjusted for asset impairments, restructuring, integration and transformation costs, acquisition-related costs and adjustments excluding amortization of intangible assets, separation costs and separation-related costs, Loss on extinguishment of debt and other non-GAAP adjustments, as these adjustments are described above and further adjusted for amortization of intangible assets and acquisition-related costs and write down of financing, as described below:

Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes the amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

Write-down of financing fees: In addition to excluding loss on extinguishment of debt, the company has excluded write-down of financing fees as this represents a loss from refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market that are not in management's control. Bausch + Lomb did not have any material write-downs of financing fees prior to the second quarter of 2025.

Adjusted net income (non-GAAP) excludes the impact of these certain items that may obscure trends in the Company's underlying performance. Management uses Adjusted net income (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the Company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance and the valuation of the Company. It is also noted that, in recent periods, our GAAP net income (loss) attributable to Bausch + Lomb Corporation was significantly lower than our Adjusted net income (non-GAAP).

Constant Currency

Constant currency change or constant currency growth is calculated by adjusting or further adjusting a measure or ratio by changes in or impact of foreign currency exchange rates. Constant currency impact is determined by comparing current period amounts adjusted to exclude currency impact, calculated using prior comparable period monthly average exchange rates, to the actual prior comparable period reported amounts. Constant currency revenue is GAAP revenue (its most directly comparable GAAP financial measure) adjusted for changes in foreign currency exchange rates. The Company uses Constant Currency Revenues (non-GAAP) and Constant Currency Revenue Growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison. Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance.

Non-GAAP Appendix

Adjusted EBITA/Adjusted EBITA Margin

Adjusted EBITA represents Operating income (loss) (its most directly comparable GAAP financial measure) adjusted to exclude amortization, fair value adjustments to inventory in connection with business combinations and integration related inventory charges and technology transfer costs, restructuring, integration and transformation costs, asset impairments, goodwill impairments, acquisition related costs, separation costs, IPO costs, separation-related costs, IPO-related costs and certain other non-GAAP charges as discussed under "Other Non-GAAP adjustments" above. Adjusted EBITA Margin (non-GAAP) is Adjusted EBITA (non-GAAP) divided by Revenues. The most directly comparable GAAP financial measure is operating income margin, which is Operating income (loss) divided by Revenues.

Management believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP), along with the GAAP measures used by management, appropriately reflect how the Company measures the business internally and sets operational goals for each of its businesses. In particular, the Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) focuses management on the Company's underlying operational results and segment performance. As a result, the Company uses Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) to assess the actual financial performance of each segment and to forecast future results as part of its guidance.

The Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of the Company's profitability and the profitability of our segments as they eliminate the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted gross profit (non-GAAP) represents gross profit (its most directly comparable GAAP financial measure) adjusted for Other revenues, Cost of other revenues, Amortization of intangible assets and fair value adjustments to inventory in connection with business combinations. In accordance with GAAP, Gross profit represents total Revenues less Costs of goods sold (excluding amortization of intangible assets) less Cost of other revenues less Amortization of intangible assets. Adjusted gross margin (non-GAAP) (the most directly comparable GAAP financial measure for which is gross margin) represents Adjusted gross profit (non-GAAP) divided by Product revenues.

Adjusted gross profit (non-GAAP) and Adjusted gross margin (non-GAAP) are measures used by management to understand and evaluate the Company's and each of its segment's pricing strategy, strength of product portfolio, ability to control product costs and the success of its go-to-market strategies. Adjusted gross profit (non-GAAP) and Adjusted gross margin (non-GAAP) facilitate period-to-period comparisons of the Company's and each of its segment's ability to generate cash flows from sales, as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are a non-cash charges.

The Company believes that Adjusted gross profit (non-GAAP) and Adjusted gross margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitate period-to-period comparisons of the Company's and each of its segments' ability to generate incremental cash flows from its revenues as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are a non-cash charges that can be impacted by, among other things, the timing and magnitude of acquisitions, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted SG&A/Adjusted SG&A Margin

Adjusted SG&A expenses (non-GAAP) represents selling, general and administrative expenses ("SG&A expenses") (its most directly comparable GAAP financial measure), adjusted to exclude separation-related costs, IPO-related costs and certain costs primarily related to legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices, as well transformation costs. See the discussion under "Other Non-GAAP adjustments" and "restructuring, integration and transformation costs" above. Management uses Adjusted SG&A (non-GAAP), along with GAAP measures, as a supplemental measure for period-to-period comparison to understand and evaluate each segment's ability to control costs and direct additional cash investments in each business. The Company believes that Adjusted SG&A (non-GAAP) is useful to investors as it provides consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our SG&A expenses, and operations, as this measure eliminates the effects of separation-related costs, IPO-related costs and legal and other professional fees which given their nature and frequency, are outside the ordinary course and relate to unique circumstances. Adjusted SG&A margin (non-GAAP) is Adjusted SG&A (non-GAAP) divided by Revenues.

Adjusted Tax Rate

Adjusted Tax Rate (the most directly comparable financial measure for which is our GAAP tax rate) includes the tax impact of the various non-GAAP adjustments used in calculating our non-GAAP measures. However, due to the differences in the tax treatment of items excluded from non-GAAP earnings, our adjusted tax rate will differ from our GAAP tax rate and from our actual tax liabilities.

Adjusted Earnings Per Share (EPS)/Adjusted EPS excluding Acquired IPR&D

Adjusted earnings per share or Adjusted EPS (non-GAAP) is calculated as Diluted income per share attributable to Bausch + Lomb Corporation ("GAAP EPS") (its most directly comparable GAAP financial measure), adjusted for the per diluted share impact of each adjustment made to reconcile Net income (Loss) attributed to Bausch + Lomb Corporation to Adjusted net income (non-GAAP) as discussed above. Adjusted EPS excluding Acquired IPR&D (non-GAAP) is Adjusted EPS (non-GAAP) further adjusted for the per diluted share impact of Acquired IPR&D. Like Adjusted net income (non-GAAP), Adjusted EPS (non-GAAP) and Adjusted EPS excluding Acquired IPR&D excludes the impact of certain items that may obscure trends in the Company's underlying performance on a per share basis. By disclosing these non-GAAP measures, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's results and trends for the periods presented on a diluted share basis. Accordingly, the Company believes that Adjusted EPS (non-GAAP) and Adjusted EPS excluding Acquired IPR&D (non-GAAP) are useful to investors in their assessment of the Company's operating performance, the valuation of the Company and an investor's return on investment. It is also noted that, for the periods presented, our GAAP EPS was significantly lower than our Adjusted EPS (non-GAAP) and Adjusted EPS less Acquired IPR&D (non-GAAP).

Non-GAAP Appendix

Adjusted Cash Flows from Operations/Adjusted Cash used in Operations

Adjusted cash flows from operations (non-GAAP)/Adjusted Cash used in Operations (non-GAAP) is Cash flow from operations/Cash used in operations (loss) attributable to Bausch + Lomb Corporation (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance proceeds, if any (ii) payments for separation costs, IPO costs, separation-related costs, and IPO-related costs (iii) payments for business transformation costs and (iv) payments for financing fees related to the modification of debt, if any. Management believes that Adjusted cash flows from operations (non-GAAP)/Adjusted Cash used in Operations (non-GAAP), along with the GAAP and non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally. The Company uses adjusted cash flows from operations (non-GAAP)/Adjusted Cash used in Operations (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes adjusted cash flows from operations (non-GAAP)/Adjusted Cash used by Operations (non-GAAP) is a useful measure to evaluate current performance amounts. As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Adjusted R&D

Adjusted R&D expenses (non-GAAP) represents research and development expenses ("R&D expenses") (its most directly comparable GAAP financial measure), adjusted to exclude certain separation-related costs. See the discussion under "Other Non-GAAP adjustments" above. Management uses Adjusted R&D (non-GAAP), along with GAAP measures, as a supplemental measure for period-to-period comparison to understand and evaluate each segment's ability to control costs. The Company believes that Adjusted R&D (non-GAAP) is useful to investors as it provides consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our R&D expenses, as this measure eliminates the effects of separation-related costs, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Net Leverage

Net Leverage is the ratio of net debt (which is calculated as total debt (its GAAP equivalent) less cash and cash equivalents) over Adjusted EBITDA (excluding Acquired IPR&D). Management believes that net leverage is an important measure of our overall liquidity position and an indicator of our ability to meet financial obligations.